DRUG Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 3.42
- P/S (TTM)
- —
- EV/EBITDA
- -0.07
Profitability & growth
- ROE (TTM)
- -15.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 0.10
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Bright Minds Biosciences Inc
Company profileBright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies for central nervous system disorders, particularly in the realms of mental health and pain management. Leveraging its proprietary drug development platform, the company is advancing a versatile pipeline of treatments that align with the increasing acceptance of psychedelic therapies in clinical settings. With a seasoned management team and a robust intellectual property portfolio, Bright Minds is well-positioned to meet the rising demand for…
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 19 VESTRY STREET, NEW YORK, NY
- Fiscal year end
- September
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer